5-(4-amino-1-propan-2-yl-3-pyrazolo[3-4-d]pyrimidinyl)-1-3-benzoxazol-2-amine and Adenocarcinoma--Clear-Cell

5-(4-amino-1-propan-2-yl-3-pyrazolo[3-4-d]pyrimidinyl)-1-3-benzoxazol-2-amine has been researched along with Adenocarcinoma--Clear-Cell* in 1 studies

Other Studies

1 other study(ies) available for 5-(4-amino-1-propan-2-yl-3-pyrazolo[3-4-d]pyrimidinyl)-1-3-benzoxazol-2-amine and Adenocarcinoma--Clear-Cell

ArticleYear
Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
    Cancer letters, 2019, Oct-01, Volume: 461

    Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzimidazoles; Benzoxazoles; Biomarkers, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Indazoles; Mice; Mice, Nude; Morpholines; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Sulfonamides; TOR Serine-Threonine Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2019